This company listing is no longer active
NXTMS Stock Overview
Nexstim Plc, a medical technology company, engages in the development of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Nexstim Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €40.40 |
| 52 Week High | €56.90 |
| 52 Week Low | €36.00 |
| Beta | 1.67 |
| 1 Month Change | 1.64% |
| 3 Month Change | -10.32% |
| 1 Year Change | -26.14% |
| 3 Year Change | -46.13% |
| 5 Year Change | -99.44% |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| NXTMS | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 1.0% | -2.0% | -1.6% |
| 1Y | -26.1% | -8.7% | 8.5% |
Return vs Industry: NXTMS exceeded the Swedish Medical Equipment industry which returned -31.6% over the past year.
Return vs Market: NXTMS underperformed the Swedish Market which returned -9.3% over the past year.
Price Volatility
| NXTMS volatility | |
|---|---|
| NXTMS Average Weekly Movement | 6.1% |
| Medical Equipment Industry Average Movement | 7.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in SE Market | 13.2% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: NXTMS has not had significant price volatility in the past 3 months.
Volatility Over Time: NXTMS's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 39 | Mikko Karvinen | www.nexstim.com |
Nexstim Plc, a medical technology company, engages in the development and marketing of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally. The company’s proprietary SmartFocus technology with 3D navigation is the navigated transcranial magnetic stimulation (TMS) approach that is used for therapeutic and diagnostic applications. It offers Navigated Brain Therapy system, a navigated brain therapy system for the treatment of major depression and chronic neuropathic pain; and Navigated Brain Stimulation (NBS) system, a navigated brain stimulation system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim Plc Fundamentals Summary
| NXTMS fundamental statistics | |
|---|---|
| Market cap | kr288.81m |
| Earnings (TTM) | kr14.79m |
| Revenue (TTM) | kr121.81m |
19.5x
P/E Ratio2.4x
P/S RatioIs NXTMS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NXTMS income statement (TTM) | |
|---|---|
| Revenue | €10.76m |
| Cost of Revenue | €1.24m |
| Gross Profit | €9.52m |
| Other Expenses | €8.21m |
| Earnings | €1.31m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
Aug 18, 2023
| Earnings per share (EPS) | 0.19 |
| Gross Margin | 88.47% |
| Net Profit Margin | 12.14% |
| Debt/Equity Ratio | 85.8% |
How did NXTMS perform over the long term?
See historical performance and comparison